UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Acoramidis shows strong benefits in treating ATTR-CM, reducing heart failure and hospitalizations.

Source
Pluang

BridgeBio Pharma announced that acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), significantly reduces serum transthyretin variability and outpatient worsening heart failure, showing early and sustained benefits. The Phase 3 ATTRibute-CM study demonstrated a 34% reduction in cardiovascular hospitalizations compared to tafamidis, with a favorable mortality trend and comparable safety. These results highlight acoramidis as a fast-acting, effective treatment option for ATTR-CM, approved in multiple regions, with ongoing data presentations planned.